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Background: Although respiratory diseases exhibit in a wide array of clinical manifestations, certain respiratory
diseases may share related genetic mechanisms or may be influenced by similar chemical stimuli. Here we explore
and infer relationships among genes, diseases, and chemicals using network and matrix based clustering methods.
Results: In order to better understand and elucidate these shared genetic mechanisms and chemical relationships
we analyzed a comprehensive collection of gene, disease, and chemical relationships pertinent to respiratory
disease, using network and matrix based analysis approaches. Our methods enabled us to analyze relationships and
make biological inferences among over 200 different respiratory and related diseases, involving thousands of
gene-chemical-disease relationships.
Conclusions: The resulting networks provided insight into shared mechanisms of respiratory disease and in
some cases suggest novel targets or repurposed drug strategies.
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The capability to catalog interactions among diseases,
chemicals, and genes into well-curated databases offers a
collective knowledge of experimental results that has
great potential for the generation of hypotheses and
meta-analyses. To date, many biological databases have
been established to catalog relationships among genes
[1], diseases [2], and chemicals [3]. Many of these databases
focus on one particular type of relational interaction, ran-
ging from protein-protein interaction databases [1], gene-
chemical databases [4], and disease-gene databases [2], and
are often constructed using data mining methods comple-
mented by manual curation. The described databases, in
many instances, serve as the foundation for a wide array of
predictive and analytical methods to examine interactions.
They can also be extended to analyze interactions among
overarching themes, including analyzing gene-chemical in-
teractions within the context of a given set of diseases or
protein-protein interactions within the context of peptide* Correspondence: StrongM@NJHealth.org
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unless otherwise stated.recognition [5,6]. Integration of multiple sources and types
of relational data remains an important and challen-
ging research area with great potential toward the de-
velopment of furthering our understanding complex
diseases and interactions.
Each year over 400,000 deaths occur in the United
States as a result of respiratory and related diseases
(RRD) [7]. Given the high prevalence and importance of
lung and respiratory diseases, we hypothesized that a
better understanding of the respiratory gene-chemical-
disease interactome would lead to better understanding
of the molecular mechanisms of lung disease, including
the environmental and drug influences, and more im-
portantly, may lead to new treatment or intervention
strategies. In this study, we focus our efforts on the ana-
lysis of gene-disease-chemical relationships, in order to
elucidate and infer novel interactions and to understand
biology pertinent to respiratory diseases using network
and matrix-based methods.
Current network and matrix-based analyses of disease re-
lationships has relied heavily on gene or protein-centric ex-
aminations [8-11], neglecting chemical features that may
also influence disease. Likewise, network analysis tech-
niques have often been developed and utilized to examine
gene or protein relationships among diseases [12], but oftentd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ence disease. In cases where genes, diseases, and chemicals
have been analyzed, often the networks are decoupled to
allow for the analysis of a single entity or relationship type,
such as the effect of a drug on a gene network or the
elucidation of molecular mechanisms in disease [13-15].
Host-pathogen studies have also largely focused on a single
relational type, predominantly protein-protein interaction
relationships [16]. Here we apply methods to investigate
gene-chemical-disease networks, in order to better under-
stand the genetic and chemical contributors of diseases,




In order to compile a comprehensive dataset to examine
gene, disease, and chemical relationships pertinent to re-
spiratory disease, we extracted information from the
Comparative Toxicogenomics Database (CTD) [4] and
the Human Protein Reference Database (HPRD). CTD
houses manually curated information pertinent to gene-
disease-chemical relationships for a wide variety of dis-
eases, and HPRD houses information focusing on
protein-protein interactions from a wide array of experi-
ments in humans and other model organisms. CTD of-
fers a conservative and expert curated source of
interactions to form networks, and HPRD uses the same
normalized gene names as CTD.
We compiled and filtered our in-house database in
two ways. The first database, we refer to as the whole re-
spiratory network (Additional file 1: Table S1), and the
second database we refer to as the therapeutic network
(Additional file 2: Table S2). The whole respiratory network
represents disease-gene, disease-chemical, chemical-gene,
and gene-gene interactions associated with respiratory
diseases. The therapeutic network, in contrast, consists of a
subset of the respiratory network, containing only che-
micals with curated therapeutic interactions with dis-
eases and the genes that interact with those chemicals.
These curated therapeutic interactions are established
using the “DirectEvidence” field from CTD. This net-
work was called the therapeutic network as a reference
to this inclusion criterion. In addition to the thera-
peutic inclusion criteria, chemical-chemical interac-
tions were also included based upon curated chemical
relationships derived from chemical gene-interaction
information. Gene-gene interactions were established
using the HPRD database [1].
To assess the directionality of chemical-gene interactions,
the uniqueness of chemical-gene and gene-chemical inter-
actions were assessed. First, chemicals with disease interac-
tions were batched queried using CTD, with an output
of curated chemical-gene interactions. Second, genes withdisease interactions were batched queried using CTD, with
an output of curated gene-chemical interactions. The
intersection between these two sets was then calculated.
In the whole respiratory network, there were 27075 total
chemical-gene and gene-chemical linkages with 13543
remaining after accounting for bi-directionality of inter-
actions. Given the small percentage of directional link-
ages (~0.05%), all links were treated as bi-directional.
The type of interaction was established for disease-
chemical, disease-gene, and chemical-gene interactions. For
disease-chemical and disease-gene interactions, there were
three types of interactions based upon CTD curation:
therapeutic, marker/mechanism, and both therapeutic and
marker/mechanism. Chemical-gene interactions had three
major effects and one minor effect based upon CTD cur-
ation. The major effects are increasing, decreasing, and af-
fecting expression or activity. The minor effect is based
upon the type of protein modification imparted by the
chemical onto the protein. The list of protein modification
includes: ubiquitination, phosphorylation, oxidation, cleav-
age, methylation, hydrolysis, hydroxylation, glycosylation,
glucuronidation, acetylation, nitrosation, ribosylation.
To establish chemical-chemical linkages and the type
of gene-chemical linkage, CTD was used [4]. Chemical-
gene interactions were extracted with a query specifying
interaction type. Co-interactions between multiple che-
micals and a gene were extracted from this list and
chemical-chemical linkages were established if two che-
micals had a curated co-occurrence with a gene. A co-
occurrence was determined when a secondary chemical
appeared in the interaction characteristics between a
chemical and a gene. The type of linkage between the
two chemicals was classified using the same type of link
used to classify chemical-gene interaction in which the
co-occurrence appeared. As there is often discordance
between the naming of chemicals, especially those with
pharmaceutical implications, a chemical reaction data-
base and drug interaction database were not utilized for
establishing chemical-chemical interactions.
After construction of the network, Jaccard similarity
coefficients were generated between all nodes. Each co-
efficient was then classified based upon whether the two
nodes were connected and the type of nodes being con-
nected. Figure 1 represents the three node interaction types
of interest: disease-gene interactions, disease-chemical in-
teractions, and chemical-gene interactions. To test the al-
ternative hypothesis that linked nodes are more similar
than unlinked nodes based upon a Jaccard coefficient,
Mann–Whitney U tests were performed on each of the
three sets with a null hypothesis that the similarity between
linked nodes and unlinked nodes is the same. In all three
cases, Mann–Whitney U tests showed with greater than
99.9% confidence that linked nodes were more similar than
unlinked nodes (p < 0.01). This suggests that the greater the
Figure 1 Similarity of linked and unlinked nodes. Jaccard
similarity coefficients between linked and unlinked nodes in the
therapeutic network. LDG – linked disease-gene, UDG – unlinked
disease-gene, LDC – linked disease-chemical, UDC – unlinked
disease-chemical, LCG – linked chemical-gene, UCG – unlinked
chemical-gene. In all three sets, the linked nodes were more similar than
unlinked nodes determined by Mann Whitney U tests (p < 0.01). The
median for all unlinked node pairs is 0, with the medians for the linked
pairs: DG – 0.026, DC – 0, CG – 0.032.
Figure 2 Gene-disease sub-network. Shared genes between
Pulmonary Fibrosis and Asthma. Many of these genes represent
similar pathophysiology in both diseases, such as activation of Th2 cell
inflammation by IL13 and IL4. Red links represent marker/mechanism links.
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act. To assess the stability of the Jaccard coefficient, single
edge additions were added to sub-networks. Kolmogorov-
Smirnov tests were then run on the Jaccard coefficient
distributions of the individual sub-network against pertur-
bations within that sub-network. The result is that no per-
turbation caused a significant shift in distribution (average
p-value ~ 0.99), with smaller sub-networks being more af-
fected by perturbations (minimum p-value ~ 0.10). This
lack of significant change is due to an addition of one edge
having only small impacts on network topology, validating
the Jaccard similarity as a stable measure of similarity for
small amounts of missing data.
Clustering methods
Evaluation of protein-protein interaction network clustering
methods is generally performed through the comparison of
gold standard regulatory networks or pathways. Since an
analogous gold standard gene-chemical-disease network
does not exist, for us to evaluate clustering methods, we se-
lected high performing methods used for clustering
protein-protein interaction networks, with the added stipu-
lation that their output is scalable to a more sparse and dis-
similar network. MCODE and MCL, two widely accepted
and utilized clustering methods were tested for scalability
when adding additional node types [11,17-19]. The gene-
gene portion of the network was used as a baseline for the
types and sizes of sub-networks that can be expected in an
ideal situation. In the gene-gene network, both algorithmsperformed similarly with median sub-network sizes of 4 for
MCODE and 3 for MCL. In the larger sub-networks both
methods displayed highly interconnected clusters. In the
therapeutic network, however, the clustering methods
performed much differently. MCODE had a median sub-
network size of 18, while still maintaining the highly inter-
connected networks, and MCL had a median cluster size of
3, and no longer exhibited an interconnected feature. We
also applied hierarchical clustering, utilizing a Pearson’s
correlation coefficient. Pearson’s has been shown to be a
highly robust unsupervised correlation that performs well
under a multitude of protein-protein interaction analyses,
from identifying regulatory networks to identifying groups
of proteins with shared functions [20,21]. A lack of a gold
standard gene-disease-chemical network is also why no
semi-supervised or supervised methods were chosen.
Node-edge analysis
For the whole respiratory network, nodes were input
based upon type (disease, chemical, gene) and edges based
upon types of nodes involved (disease-gene, gene-gene,
chemical-gene, disease-chemical) into Cytoscape [22], cre-
ating a network of 1,830 nodes and 17,275 edges. This
network became a test-bed for methods to improve subse-
quent analyses including constructing networks with only
one type of edge, and networks with filtered diseases,
chemicals, and genes of interest. These tests led to the
creation of both a gene-disease sub-network and the
therapeutic chemical network.
The gene-disease sub-network was visualized by Cytos-
cape to determine clusters of similar genes not seen in the
overall network. Figure 2 shows one such cluster of shared














Counts of each type of node and linkage for both the whole respiratory
network and the therapeutic network.
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genes we observe linked to pulmonary fibrosis and asthma,
we see the IL4 and IL13 cytokines. Both IL4 and IL13 are
involved in activating Th2 cell inflammation, involved in
asthma. Both IL4 and IL13 antagonists have also been
shown to be effective in asthma therapy through the damp-
ening of inflammation associated with asthma. In addition
to being involved in asthma, IL13 has also been linked to
pulmonary fibrosis, stimulated by the activation of Th2 cell
inflammation, leading to tissue fibrosis. TGFB1 also induces
inflammation, apoptosis, and fibrosis in mouse models
[23,24], and has been associated with asthma. Networks
such as these may be used to identify shared genetic mech-
anisms or molecular pathways of disease, and can also be
used to identify novel drug targets or repurposed drug
strategies to combat diseases that may be clinically very dif-
ferent, but that may share common genetic or molecular
relationships.
For the therapeutic network, full information about the
interaction between nodes was input into Cytoscape and vi-
sualized using an organic graph layout [22]. Nodes were
colored by disease, chemical, or gene. Edges were colored
by positive interactions (therapeutic or increases), negative
interactions (marker/mechanism or decreases), mixed in-
teractions (affects or therapeutic with marker/mechanism),
and color intensity weighted by any protein modifications.
Based upon database inclusion criteria, there were 388
genes, 227 diseases, and 578 chemicals. There were 10,679
linkages between these nodes, with each linkage having a
characteristic path length of 3 and each node having an
average of 18 neighbors. These numbers are about half that
of the whole respiratory network, both decreasing the size
of the network and making the network more directed to-
wards finding positive interactions between chemicals and
diseases. Linkage statistics from both networks can be seen
in Table 1. A schematic of the overall process of creating
and analyzing the therapeutic network can be seen in
Figure 3.
To elucidate clusters of interest, the Cytoscape plugin
MCODE was run on the network using a degree cutoff
of 2, a node score cutoff of 0.2, a K-Core of 2, and a
max depth of 100 [17]. This resulted in 18 highly inter-
connected clusters with a diverse set of node types
(Additional file 3: Table S3), allowing the therapeutic
network to be investigated and parsed into manageable
sub-networks. These sub-networks offer a more manage-
able network to elucidate and identify novel and relevant
interactions. Figure 4 demonstrates two of these sub-
networks. Non-connected nodes that occur in highly
interconnected sub-networks, particularly those with
shared neighbors, offer a refined starting point for infer-
ring novel interactions. Connections of interest were in-
vestigated by randomly choosing 23 unlinked node-pairs
from the resulting sub-networks. These 23 inferred linkswere then analyzed by manually mining literature and
databases for evidence that the two nodes might be
linked by methods beyond those we used to establish
our networks. In the absence of a gold standard, manual
literature mining is often used to for validating infer-
ences [25]. Supporting evidence for these inferred links
can be seen in Table 2.
One of these sub-networks, shown in Figure 4A, con-
tains non-small-cell lung carcinoma and closely interact-
ing genes and chemicals. From this sub-network, three
links were analyzed in greater detail: aspirin - EGFR,
acetaminophen - non-small-cell carcinoma, and piroxi-
cam - non-small-cell carcinoma. Aspirin - EGFR is an
inferred link in this sub-network that was added as a dir-
ect link to an update of CTD that occurred after the cre-
ation of this network [4]. There was strong support in
literature for aspirin promoting EGFR inhibitors, enough
for a curated interaction between these two elements
[26,27]. This link represents a verified prediction both by
literature and by CTD, representing the effectiveness of
using sub-networks to find novel links. Acetaminophen -
Non-small-cell lung carcinoma is a link that has negative
support in literature [28]. In studies involving testing
multiple anti-inflammatory drugs for change in non-
small-cell lung carcinoma outcome, they found no correl-
ation between Acetaminophen and change in prognosis
[28]. The negative support for this link shows that while
sub-networks offer a starting point for testing inferred in-
teractions, not all of the nodes will have a direct link. Lastly,
Piroxicam - non-small-cell carcinoma had direct and indir-
ect literature support for this link [29,30]. There was in-
creased immune function in lung cancer patients that had
piroxicam added to their drug regimens [29]. Also, piroxi-
cam showed decreased tumorigenesis in mice with colon
Figure 3 Network analysis flowchart. Interaction development pipeline for extracting interaction and node information from CTD and HPRD,
construction of network from interaction information, creating sub-networks from the network and clusters from the matrix, and identifying
biologically relevant information to make novel inferences.
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Figure 4 Visualization of sub-network interactions. A) Clustered sub-network containing non-small-cell lung carcinoma and a restricted view
of closely interacting chemicals and genes for visualization purposes. B) Clustered sub-network containing Cystic Fibrosis and closely interacting
diseases, chemicals, and genes.
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cers as well [30]. This link represents a possible avenue for
further research. There is evidence to support that there
are beneficial effects of piroxicam on non-small-cell carcin-
oma prognosis; however, the full effects of this interaction
are not well understood.
Analysis of sub-networks also presents the ability to find
links for similar or comorbid diseases. In the cystic fibrosissub-network, Figure 4B, dobutamine interacts with both
of cystic fibrosis’ genes in the sub-network, suggesting a
link between dobutamine and cystic fibrosis. Upon search-
ing the literature, dobutamine, especially in combination
with nitric oxide, improves pulmonary hypertension in
cystic fibrosis patients, a common comorbidity [31]. CTD
neither contains a link between dobutamine and cystic
fibrosis nor dobutamine and pulmonary hypertension.
Table 2 Inferred interaction summary
Link Inferred links Literature support Expression support Database support Anti-support No support
Gene-disease 10 9 0 3 0 1
Gene-chemical 9 3 5 1 1 4
Chemical-disease 4 2 0 1 1 0
Type of inferred link and support for each link. Inferred link is number of currently non-linked node pairs analyzed in each category. Literature support means a
PubMed search resulted in a published article that supports the link. Expression support means there is literature support for gene expression changes. Database
support means that there is support for a link due to curation methodology or the link was added in later version of CTD. Anti-support means that literature
specifically says this link is not real, and no support means that no evidence could be found for or against the link.
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sub-network. These coefficients measured similarity using
only nodes and links present within the sub-network. Simi-
larities were then averaged for each node, representing how
similar a given node is to the sub-network as a whole. The
same 23 unlinked node pairs from the previous analysis
were used to determine the relationship between similarity
and literature evidence. Similarity between the two nodes
was ranked against the similarity of all other pairwise Jac-
card coefficients within the sub-network, with the similarity
being broken into one of three sets: upper 25th percentile,
middle percentile, and the lower 25th percentile. These
comparisons represent how similar the two nodes are to
each other, relative to the sub-network as a whole. Evidence
for a possible interaction was then manually mined from
published articles, and then compared to their similarity
classifications. Table 3 represents mined literature support
against similarity classification. With increasing similarity
between the two nodes, relative to their ranked similarities
within the sub-network, there was increasing evidence in
literature to support connection between the two nodes. In
addition to having a greater likelihood of evidence based
upon similarity, just being in the same sub-network in-
creased the likelihood of two nodes having a connection
over the 0.015 probability of any two random nodes being
linked together in the databases used for constructing the
network. This shows a complimentary relationship between
clustering and similarity when trying to determine if there
is evidence to support two nodes being linked.
A more systematic evaluation of the relationship be-
tween Jaccard similarity and identifying novel links was
performed on a human signaling network [32]. Protein-
Protein interactions from the human signaling network
were selected based upon both the interacting genes
being present in the therapeutic network while theirTable 3 Jaccard similarity assessment




Supporting evidence for and inferred linkage utilizing the Jaccard coefficient between tw
compared to the ability to find evidence supporting the pairwise connection. A rank of 1
of 0 represents the lowest Jaccard coefficient within the sub-network.interaction was not present in the network. While self-
interacting genes were utilized in generating Jaccard
similarity values, they were excluded from both the
background and the human signaling network during
the analysis. This is due to the fact there is no way to
distinguish between likely self-interactions and unlikely
self-interactions using a similarity measure that will al-
ways be 1.0 in the case of a self-interaction. This selec-
tion resulted in 1057 additional interactions for use in
validation.
A Mann–Whitney U test was performed on the hu-
man signaling network gene-gene interactions with the
null hypothesis that there is no similarity difference from
the background of possible gene-gene interactions. The
alternative hypothesis is that the novel interactions from
the human signaling interactions are more similar than
the background. This test resulted in a p < 0.01, showing
that these novel interactions are more similar than the
background. Just as the literature study, rank of the Jac-
card coefficient was also important to whether or not an
interaction was found. There was an exponential rela-
tionship between the rank and inclusion into the human
signaling network with roughly 40% of the additional in-
teractions being in the 90th percentile or greater
(Figure 5).
Matrix analysis
A binary interaction matrix was created using the net-
work interaction triples for both the whole respiratory
and therapeutic networks, Values of 1 represent an inter-
action; whereas, values of 0 represent a lack of interac-
tions. These matrixes were then used as input to Cluster
3.0, an open source clustering tool [33]. An uncentered
similarity matrix with average linkage was used to calcu-




o nodes. The rank of the pairwise Jaccard coefficient within the sub-network was
00 represents the highest Jaccard coefficient within the sub-network and a rank
Figure 5 Jaccard rank of human signaling network interactions.
Percent of gene-gene interactions that fall into a given percentile
range (broken into ranges of 10 percent) for both the background
of possible interactions and the novel interactions represented by
the human signaling network (HSN). A lower bound of the 10th
percentile represents the range of greater than the 10th percentile
to less than or equal to the 20th percentile. The discrepancy in that
the background percentiles are not exactly equal to 10% is due to
the fact that duplicates of Jaccard coefficients at the boundary
percentiles were treated the same as the boundary.
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from the therapeutic matrix are shown in Figure 6.
Individual clusters from the therapeutic matrix were
established using a 0.7 and 0.4 similarity threshold. Both
of these thresholds were chosen as they represent inflec-
tion points in the node count versus similarity graph, as
shown in Figure 7. Inflection points represent possible
changes in cluster characteristics, such as separating
high similarity clusters with medium similarity clusters.
The 0.7 threshold resulted in 71 clusters. The smallest
cluster had 2 nodes and the largest with 13 nodes. The
0.4 threshold resulted in 211 clusters (Additional file 4:
Table S4). The smallest cluster had 2 nodes and the lar-
gest with 45 nodes. The 0.7 threshold offers the highest
similarity between nodes; however, it often results in the
inclusion of nodes that only have a few total number of
interactions. The ERBB gene family was found in the 0.4
threshold but not in the 0.7 threshold. Also, the 0.4
threshold included both expansions and additions of
clusters, such as the expansion of and anti-histamine
cluster to include additional anti-histamines, and the
addition of a tumorigenesis gene cluster. This expanded
set of clusters supports the idea that the 0.4 threshold is
more useful for finding clusters of similar function, while
still maintaining a similar specificity as the clusters
found in the 0.7 threshold.Unlike sub-networks, clustering of the matrix eluci-
dates families of chemicals, genes, and diseases with
similar phenotypes and chemical characteristics. Figure 8
shows clusters in each of these three node categories
from a similarity cutoff of 0.4. These clusters contain a
group of beta2-agonists (Figure 8A), ERBB family pro-
teins (Figure 8B), and a group of fungal lung diseases
(Figure 8C). For the matrix clusters, genes had a ten-
dency to cluster with other genes, chemicals with other
chemicals, and diseases with other diseases. Almost all
of the clusters were made up of elements of the same
type, supporting the idea that this matrix clustering ap-
proach is suitable for finding nodes with similar properties
versus the more diverse interactomes in the traditional sub-
networks.
The assertion that subclusters can identify nodes with
similar properties can be used for predicting interactions
by analyzing overlap between cluster nodes and their
shared interactions. In a cluster containing SEPP1, GJB1,
SELENBP1, SLC22A18, A2M, and PDFGA, five out of
the six genes in this cluster have an association with
lung neoplasms. PDGFA, the gene not linked with lung
neoplasms, has associations with breast, prostate, head
and neck, and pancreas cancers. In addition, PDGFA in-
creases with asbestos exposure, a chemical linked to
mesothelioma [35]. This increase is also associated with
tumorigenicity, supporting the assertion that PDFGA is
also a marker for lung neoplasms [35].
Ebastine, levocabastine, hydroxyzine, SUN1334H, azelas-
tine, olopatadine, cetirizine, desloratadine, sho-seiryu-to,
epinastine, and tripolidine are a group of anti-histamine
drugs that target HRH1, all of which also have interactions
with rhinitis. These anti-histamine drugs also have anti-
inflammatory properties, revealed by seven drugs having
links to IL4, four having links to IL5, and four having links
to IL8. This is supported by a study that shows various
anti-histamines having anti-inflammatory properties in
rhinitis pathology [36].
MT2, MT1, CCL9, CCL8, ECM1, and SLC39A4 repre-
sent a diverse cluster of two metallothionein proteins,
two macrophage proteins, one extracellular matrix pro-
tein, and one zinc transporter protein. Many of these
genes regulate metal concentrations within cells and are
linked to respiratory hypersensitivity. Out of the five
shared chemicals, only acetaminophen is linked to re-
spiratory hypersensitivity. However, four out of these five
chemicals have links to asthma, suggesting they may
play a greater role in respiratory hypersensitivity in gen-
eral. This hypothesis is supported by the fact that zinc
deficiency alters respiratory epithelium in allergic re-
sponse of mice [37].
Ofloxacin, amoxicillin clavulanate, clarithromycin, and
azizthromycin are a group of antibiotics that treat re-
spiratory infections. The interactome of these antibiotics
Figure 6 Therapeutic diffusion matrix. Therapeutic matrix clustered based upon uncentered Pearson’s correlation coefficient with average
linkages and then hierarchical clustering. Each red dot represents an interaction pair with the rows and columns representing nodes. The green
represents diffusion to aid in visualizing the sparse network. Node ordering is based upon similarity to adjacent nodes.
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mycin and ofloxacin have direct links to tuberculosis in
CTD. The drug combination amoxicillin-clavulanate has
literature support that it is effective in treating tubercu-
losis, whereas; amoxicillin alone is ineffective [38,39].
This increase in effectiveness with clavulanate is due to
the fact clavulanate inhibits an enzyme that makes
Mycobacterium tuberculosis resistant to amoxicillin
[38,39]. While literature shows that azithromycin alone
is also ineffective in treating tuberculosis isolates, lit-
erature shows that azithromycin in combination with
capreomycon, pyrazinamide, ethambutol, and isoniazid
improves outcomes in multi-drug resistant patients
over streptomycin, ethambutol, pyrazinamide, and iso-
niazid [40,41]. Given the fact that tuberculosis is often
treated with a combination of drugs, further evaluation
of amoxicillin-clavulanate and azithromycin within the
context of a drug regimen would offer a more practical
approach to evaluating the effectiveness of treating tu-
berculosis patients with these antibiotics. Also of noteare the links from azithromycin and clarithromycin to
IL6 and IL4 respectively. It is thought that even though
azithromycin does not directly kill M. tuberculosis in
cell culture, it may have a pro-immune effects that im-
proves outcomes of tuberculosis patients, or may play
a role as an anti-inflammatory. BCL2L1 is affected by
clarithromycin, a known tuberculosis drug, and azi-
thromycin, an inferred TB drug. This coupled with a
shared interaction of CCL2 between tuberculosis and
azithromycin promotes that idea that azithromycin
may have a therapeutic effect on tuberculosis through
an anti-inflammatory response. Through the analysis
of gene-disease-chemical networks we may gain better
insight into both the direct target and off target activ-
ities of certain drugs, useful in the identification of
drug repurposing strategies.
Node-edge versus matrix
While these two approaches take the same input, clus-
tering produces two distinct results. Only eight of the
Figure 7 Matrix similarity graph. Number of hierarchical clustered
nodes represented by a static cutoff for a given uncentered
Pearson’s correlation coefficient. The inflection point at ~ 0.4
similarity was used to generate clusters for analysis.
Figure 8 Clusters of elements from 0.4 similarity cutoff. A)
Beta2-agonists B) ERBB family proteins. C) Fungal lung diseases; A, ABP –
Aspergillosis, Allergic Bronchopulmonary; LD, F – Lung Disease, Fungal;
PA – Pulmonary Aspergillosis.
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where at least 50% of the nodes present in the matrix clus-
ter were also present in the sub-network. Most of the
matrix clusters that overlapped with the sub-networks con-
tained only two or three nodes. However, one sub-network
contained 11 of the 28 nodes in one matrix subcluster,
making it the most nodes shared between a sub-network
and a matrix cluster. These differences can be attributed to
both network construction and the types of interactions
that are obtained from each approach. Given the sparsity of
the network, especially in chemical-chemical interactions,
and the lack of disease-disease interactions, clustering coef-
ficients and pairwise comparisons produce non-overlapping
results. Clustering coefficients from node-edge based ap-
proaches represent closely interacting genes, chemicals, and
diseases. These closely interacting nodes offer avenues of
exploration for finding novel interactions. Pairwise compar-
isons from matrixes represent nodes that share the same
interaction profile. This interaction profile can then be used
for determining both biological meaning and novel interac-
tions for any pairs between the cluster nodes and the inter-
action profile nodes. Thus, these two approaches offer a
complimentary analysis strategy for sparse networks, enab-
ling elucidation of both novel interactions and increasing
our biological understanding of node clusters.
The second distinction these two approaches offer is in
the visualization of interactions. Node-edge network ap-
proaches illustrate which nodes form a sub-network,
which nodes interact within these sub-networks, and the
types of interactions between each node, giving an all
encompassing view of the sub-network. Matrix-based ap-
proaches provide a broader view of interactions, offering atool for visualizing not only how similar nodes and clus-
ters are to each other, but also the interactions nodes
share outside of their individual clusters.
Conclusion
Current network analyses of disease are still highly fo-
cused on gene and protein-based networks, neglecting
environmental and drug effects that contribute to the
pathophysiology of a disease or sets of diseases. Our pro-
posed methods integrate both the chemical and disease
entities into network and matrix-based analyses, allow-
ing for a more complete systems understanding of the
underlying biology. With this addition of multiple differ-
ent entity types comes the lack of a gold standard for
identifying specific genes, chemicals, and diseases that
should cluster together, providing a similar role as the
curated regulatory and pathway networks used to estab-
lish accuracy in protein-protein and gene-gene network
analyses.
In order to better investigate complex and sparse net-
works, such as the respiratory disease interactome, a multi-
method approach utilizing methods proven effective in
gene-gene and protein-protein network-based analyses has
proven useful to elucidate and investigate different network
properties and the underlying biological context. In this
case we have used two approaches: a node-edge-based clus-
tering coefficient with Jaccard similarity comparison ap-
proach applied to traditional networks, and a matrix-based
Pearson’s correlation coefficient with hierarchical clustering
approach. This allows identification of closely interacting
diseases, chemicals, and genes, as well as similar interaction
profiles either within or between these same elements of
interest. These two approaches help facilitate investigations
Figure 9 Matrix cluster interactome. Cluster of oflaxacin, amoxicillin-clavulanate (Amox-Clav), azithromycin, and clarithromycin with closely
interacting genes and diseases.
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physiology similarities across diseases, and chemicals
that may have a therapeutic indication outside of their
original use.
The shared interactome of four therapeutic antibiotics
(ofloxacin, amoxicillin clavulanate, clarithromycin, and
azizthromycin, (Figure 9) allows for an inference of
interaction between azithromycin and tuberculosis based
upon the interaction profile of a cluster generated by
hierarchically clustering a Pearson’s correlation coeffi-
cient matrix. This profile represents the layering of dis-
eases, chemicals, genes and the interactions between
them, showing that while azithromycin has no known
anti-Mycobacterium tuberculosis properties, it does have
pro-host immune properties that may have therapeutic
merit for tuberculosis treatment.
These methods are also useful for finding drug tar-
gets. The shared interactome of pulmonary fibrosis
and asthma (Figure 1) demonstrates that Th2 cell in-
flammation is an important factor in both of these dis-
eases, where a drug that improves the outcomes in one
of these diseases may also be useful for the other dis-
ease. Looking at these interactomes provides a broader
context for drug discovery and drug repurposing.Chemical, gene, and disease interactomes offer a novel
approach to not only identify shared biology among dis-
eases, but also offer a method for identifying possible
new drug targets and repurposed drug strategies. Layer-
ing additional interaction information, additional data-
bases, and additional analysis techniques will allow for a
more complete systems-based analysis that will extend
to any complex disease interactome.
Methods
Network generation
Respiratory diseases and the curated chemical and genes
interactions with these diseases were extracted from
CTD using the January 9, 2012 database version [4].
Curated chemical-gene interactions were extracted
from batch queries using the chemicals and genes as-
sociated with respiratory diseases. Genes, chemicals,
and their associated links that did not contain a link
to a respiratory disease were removed from the list.
Duplicates of gene-chemical and chemical-gene links
were also removed from this list. Gene-gene interac-
tions were established using the April 13, 2010 version
of the HPRD database [1]. Genes and their associated
interactions were excluded from the list if they did not
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teractions were further specialized by including only
chemicals with therapeutic interactions to respiratory
diseases in a therapeutic network, with the “thera-
peutic” name stemming from including only chemicals
with at least one therapeutic indication. The thera-
peutic indication for a chemical is determined from the
by the direct evidence field from CTD. Genes were
then excluded if they did not contain a link to one of
these therapeutic chemicals. Chemical-chemical links
and chemical-gene interaction characteristics for the
therapeutic network were established using the February
10, 2012 version of CTD [4]. Chemical-chemical links
were established using co-occurrence of chemicals in
chemical-gene interactions. A chemical was established
as co-occurring when a secondary chemical appeared
in the interaction characteristics of chemical-gene interac-
tions. A triple was stored for each interaction, including
both interacting nodes and the type of interaction between
them.
Network and matrix visualization
A file containing the triples of interactions and a file
containing the type of node (chemical, gene, disease)
were loaded into Cytoscape [22]. Nodes were colored
based upon their type, with chemicals represented as
blue, genes as black, and diseases and orange. Interac-
tions were colored based upon interaction characte-
ristics, with positive interactions as green, negative
interactions as red, mixed interactions as purple, and
additional characteristics as increasing intensity.
A binary interaction matrix between nodes was created
using the network construction file containing interaction
triples. A value of 1 was used for any interaction type be-
tween nodes and a value of 0 was used for a lack of inter-
action between nodes. This binary interaction matrix was
visualized by creating a bitmap of clustered interactions
and the resulting dendrograms by using TreeView [34].
Network and matrix clusters
MCODE, a Cytoscape plugin, was used to generate each
of the sub-networks [17,22]. A degree cutoff of 2, and
node score cutoff of 0.2, a k-core of 2, and a max depth
of 100 were used as the MCODE parameters for gener-
ating clusters.
Cluster 3.0 was used to generate clusters for this matrix
[33]. An uncentered similarity with average linkage was
used to calculate the hierarchical clustering. Similarity
scores of 0.4 and 0.7 were used for creating clusters, based
upon inflection points Figure 7.
Jaccard similarity
Jaccard similarity coefficients were generated for both
the therapeutic network and for sub-networks using thefollowing formula: Node1 ∩ Node2Node1þNode2− Node1 ∩ Node2ð Þ. This formula
calculates the intersection of the two sets divided by
their union. A set, in all cases, is all the nodes that inter-
act with a given node, including any self-interactions.
The intersection of two nodes is all shared interactions
between the two nodes, with the union of the two nodes
being all the nodes that interact with at least one of the
nodes of interest. For the entire therapeutic network, a
Mann–Whitney U test was run with the alternative hypoth-
esis that linked nodes are more similar than unlinked
nodes. For sub-networks, ranks of Jaccard coefficients were
calculated using the individual sub-network that a node
pair come from and then compared to the evidence of there
being an interaction.Network stability
Sub-networks were used to assess the stability of the
network in respect to changes in Jaccard coefficient. For
a given sub-network, an additional network was gener-
ated for each missing edge. In each of these networks
one additional edge was added between two existing un-
linked nodes, creating a unique set of networks. Jaccard
coefficients were then generated for each additional net-
work. Two-sample Kolmogorov-Smirnov tests were used
to assess whether or not the distribution of the original
sub-network and the altered sub-networks was shifted.
This was done for each of the sub-networks and their
corresponding altered networks. The null hypothesis was
that the Jaccard coefficient distribution of the network
with an additional edge is the same as the unaltered sub-
network, with the alternative hypothesis being that the
distribution is shifted.Programming
Original network parsing to establish interactions be-
tween nodes was done using perl version 5.12.4 on Mac
OSX 10.7. This includes parsing interactions between
genes, chemicals, and diseases, finding which chemicals
have co-interactions with genes, finding unique interac-
tions and directional interactions between chemicals and
genes, finding interaction characteristics for disease-gene
and disease-chemical interactions, and selecting inclu-
sion criteria for interactions of interest to develop each
network.
Further network parsing, matrix construction, and
dendrogram parsing was done using C#/.NET 4.0 on a
Windows 7 machine. This includes finding specific inter-
action characteristics for chemical-gene and chemical-
chemical interactions, construction of the interaction
matrix, visualization of the interaction matrix, and
extracting clusters based upon a threshold from the out-
put from Cluster 3.0.
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